Published in Cell Metab on January 04, 2012
Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell (2012) 9.88
MYC on the path to cancer. Cell (2012) 8.65
Links between metabolism and cancer. Genes Dev (2012) 5.27
Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov (2013) 4.72
Fueling immunity: insights into metabolism and lymphocyte function. Science (2013) 3.62
Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest (2013) 3.46
Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell (2013) 3.32
Cancer cell metabolism: one hallmark, many faces. Cancer Discov (2012) 3.03
The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell (2013) 2.70
Memory CD8(+) T cells use cell-intrinsic lipolysis to support the metabolic programming necessary for development. Immunity (2014) 2.63
A two-way street: reciprocal regulation of metabolism and signalling. Nat Rev Mol Cell Biol (2012) 2.35
Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol (2015) 2.35
Therapeutic targets in cancer cell metabolism and autophagy. Nat Biotechnol (2012) 2.27
MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb Perspect Med (2013) 2.19
Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proc Natl Acad Sci U S A (2012) 2.02
Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer Cell (2012) 1.98
Heterogeneity of tumor-induced gene expression changes in the human metabolic network. Nat Biotechnol (2013) 1.91
MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Invest (2013) 1.89
Acetate dependence of tumors. Cell (2014) 1.80
Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A (2013) 1.76
Pyruvate carboxylase is critical for non-small-cell lung cancer proliferation. J Clin Invest (2015) 1.74
ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. Cancer Cell (2012) 1.71
Targeting mitochondria metabolism for cancer therapy. Nat Chem Biol (2015) 1.68
Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. J Clin Invest (2015) 1.67
Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport. Mol Cell (2014) 1.63
c-Myc and cancer metabolism. Clin Cancer Res (2012) 1.60
Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Cancer Cell (2015) 1.58
Glutamine-driven oxidative phosphorylation is a major ATP source in transformed mammalian cells in both normoxia and hypoxia. Mol Syst Biol (2013) 1.56
Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism. Proc Natl Acad Sci U S A (2012) 1.54
Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation. Nat Cell Biol (2016) 1.51
Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res (2013) 1.49
A mitochondrial RNAi screen defines cellular bioenergetic determinants and identifies an adenylate kinase as a key regulator of ATP levels. Cell Rep (2014) 1.48
The acetate/ACSS2 switch regulates HIF-2 stress signaling in the tumor cell microenvironment. PLoS One (2015) 1.47
Understanding metabolic regulation and its influence on cell physiology. Mol Cell (2013) 1.43
IKKβ promotes metabolic adaptation to glutamine deprivation via phosphorylation and inhibition of PFKFB3. Genes Dev (2016) 1.41
A guide to immunometabolism for immunologists. Nat Rev Immunol (2016) 1.41
Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers. J Clin Invest (2017) 1.40
Mitochondria in the regulation of innate and adaptive immunity. Immunity (2015) 1.40
Asparagine plays a critical role in regulating cellular adaptation to glutamine depletion. Mol Cell (2014) 1.36
Hypoxia-Mediated Increases in L-2-hydroxyglutarate Coordinate the Metabolic Response to Reductive Stress. Cell Metab (2015) 1.34
Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene. Oncotarget (2013) 1.32
Regulation of substrate utilization by the mitochondrial pyruvate carrier. Mol Cell (2014) 1.30
MYC, Metabolism, and Cancer. Cancer Discov (2015) 1.29
Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies. Cancer Biol Med (2014) 1.27
Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. J Med Chem (2012) 1.27
Control of glutamine metabolism by the tumor suppressor Rb. Oncogene (2013) 1.25
Targeting cancer metabolism. Clin Cancer Res (2012) 1.21
Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol Syst Biol (2014) 1.21
IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism. Cancer Res (2014) 1.19
Metabolic reprogramming and metabolic dependency in T cells. Immunol Rev (2012) 1.18
Mitochondria as biosynthetic factories for cancer proliferation. Cancer Metab (2015) 1.17
Hypoxic regulation of glutamine metabolism through HIF1 and SIAH2 supports lipid synthesis that is necessary for tumor growth. Cell Metab (2014) 1.15
Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment. J Clin Invest (2015) 1.15
PEPCK Coordinates the Regulation of Central Carbon Metabolism to Promote Cancer Cell Growth. Mol Cell (2015) 1.14
mzMatch-ISO: an R tool for the annotation and relative quantification of isotope-labelled mass spectrometry data. Bioinformatics (2012) 1.13
Metabolic reprogramming for producing energy and reducing power in fumarate hydratase null cells from hereditary leiomyomatosis renal cell carcinoma. PLoS One (2013) 1.12
Therapeutic strategies impacting cancer cell glutamine metabolism. Future Med Chem (2013) 1.12
Targeting SREBP-1-driven lipid metabolism to treat cancer. Curr Pharm Des (2014) 1.11
The mTORC1/S6K1 pathway regulates glutamine metabolism through the eIF4B-dependent control of c-Myc translation. Curr Biol (2014) 1.10
The proline regulatory axis and cancer. Front Oncol (2012) 1.10
Regulation of mitochondrial bioenergetic function by hydrogen sulfide. Part II. Pathophysiological and therapeutic aspects. Br J Pharmacol (2014) 1.10
Fundamentals of cancer metabolism. Sci Adv (2016) 1.09
MYC and metabolism on the path to cancer. Semin Cell Dev Biol (2015) 1.09
Regulation of mammalian nucleotide metabolism and biosynthesis. Nucleic Acids Res (2015) 1.08
Isotopically nonstationary 13C flux analysis of Myc-induced metabolic reprogramming in B-cells. Metab Eng (2012) 1.08
MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism. Proc Natl Acad Sci U S A (2015) 1.07
Germinal center B cell maintenance and differentiation are controlled by distinct NF-κB transcription factor subunits. J Exp Med (2014) 1.07
cMyc-mediated activation of serine biosynthesis pathway is critical for cancer progression under nutrient deprivation conditions. Cell Res (2015) 1.06
Pluripotent stem cell energy metabolism: an update. EMBO J (2014) 1.05
Molecular Pathways: Targeting MYC-induced metabolic reprogramming and oncogenic stress in cancer. Clin Cancer Res (2013) 1.04
Dysregulated metabolism contributes to oncogenesis. Semin Cancer Biol (2015) 1.03
Mitochondria and Cancer. Cell (2016) 1.02
Conceptual framework for cutting the pancreatic cancer fuel supply. Clin Cancer Res (2012) 1.02
Tumor suppressor WWOX regulates glucose metabolism via HIF1α modulation. Cell Death Differ (2014) 1.00
Altered energy metabolism in cancer: a unique opportunity for therapeutic intervention. Cancer Biol Ther (2012) 1.00
Is cancer a metabolic disease? Am J Pathol (2013) 0.99
NRF2 and p53: Januses in cancer? Oncotarget (2012) 0.98
Inhibition of cancer cell proliferation by PPARγ is mediated by a metabolic switch that increases reactive oxygen species levels. Cell Metab (2014) 0.97
Novel therapeutic targets for pancreatic cancer. World J Gastroenterol (2014) 0.96
Active glutaminase C self-assembles into a supratetrameric oligomer that can be disrupted by an allosteric inhibitor. J Biol Chem (2013) 0.96
Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors. Proc Natl Acad Sci U S A (2015) 0.96
Bridging epigenetics and metabolism: role of non-essential amino acids. Epigenetics (2013) 0.95
Glucose-dependent de novo lipogenesis in B lymphocytes: a requirement for atp-citrate lyase in lipopolysaccharide-induced differentiation. J Biol Chem (2014) 0.95
Mechanism by which a recently discovered allosteric inhibitor blocks glutamine metabolism in transformed cells. Proc Natl Acad Sci U S A (2014) 0.95
Applications of NMR spectroscopy to systems biochemistry. Prog Nucl Magn Reson Spectrosc (2016) 0.95
Targeting mitochondrial metabolism by inhibiting autophagy in BRAF-driven cancers. Cancer Discov (2014) 0.94
ROS homeostasis and metabolism: a dangerous liason in cancer cells. Cell Death Dis (2016) 0.94
Redox control of glutamine utilization in cancer. Cell Death Dis (2014) 0.93
[(18)F](2S,4S)-4-(3-Fluoropropyl)glutamine as a tumor imaging agent. Mol Pharm (2014) 0.93
ErbB2 activation upregulates glutaminase 1 expression which promotes breast cancer cell proliferation. J Cell Biochem (2014) 0.92
GRP78 enhances the glutamine metabolism to support cell survival from glucose deficiency by modulating the β-catenin signaling. Oncotarget (2014) 0.92
Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer. World J Gastroenterol (2014) 0.91
The RNA-binding protein HuR is essential for the B cell antibody response. Nat Immunol (2015) 0.91
Coordination of nutrient availability and utilization by MAX- and MLX-centered transcription networks. Cold Spring Harb Perspect Med (2013) 0.91
Metabolic consequences of oncogenic IDH mutations. Pharmacol Ther (2015) 0.90
Knockdown of malic enzyme 2 suppresses lung tumor growth, induces differentiation and impacts PI3K/AKT signaling. Sci Rep (2014) 0.90
Glutaminase activity determines cytotoxicity of L-asparaginases on most leukemia cell lines. Leuk Res (2015) 0.90
Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells. Mol Oncol (2015) 0.90
Protein Kinase A Activation Promotes Cancer Cell Resistance to Glucose Starvation and Anoikis. PLoS Genet (2016) 0.89
Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 49.82
On the origin of cancer cells. Science (1956) 49.55
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2009) 19.65
Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A (2007) 15.88
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature (2009) 13.28
HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab (2006) 13.22
TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell (2006) 11.85
Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A (2008) 11.71
Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer (2011) 9.68
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature (2011) 8.03
Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature (2011) 7.94
Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev (2008) 7.87
Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci U S A (1998) 6.90
Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab (2005) 6.85
Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature (2011) 6.57
Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol (2007) 6.54
Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov (2011) 5.79
Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev (2011) 5.64
Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci U S A (2011) 5.24
Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol Cell Biol (2005) 4.99
Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature (2011) 4.32
MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res (2009) 4.32
Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene (2006) 4.05
Control of cell growth by c-Myc in the absence of cell division. Curr Biol (1999) 3.90
Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol (2007) 3.51
Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc Natl Acad Sci U S A (2011) 3.39
Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res (2010) 3.30
Altered regulation of metabolic pathways in human lung cancer discerned by (13)C stable isotope-resolved metabolomics (SIRM). Mol Cancer (2009) 3.05
IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med (2010) 2.83
Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer Res (2010) 2.77
Quantifying reductive carboxylation flux of glutamine to lipid in a brown adipocyte cell line. J Biol Chem (2008) 2.76
The role of high rates of glycolysis and glutamine utilization in rapidly dividing cells. Biosci Rep (1985) 2.73
Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem J (2007) 2.52
Glutamine metabolism in lymphocytes: its biochemical, physiological and clinical importance. Q J Exp Physiol (1985) 2.44
Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res (2002) 2.29
Global identification of Myc target genes reveals its direct role in mitochondrial biogenesis and its E-box usage in vivo. PLoS One (2008) 2.12
Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. Cancer Res (2009) 1.96
Full-length human glutaminase in complex with an allosteric inhibitor. Biochemistry (2011) 1.88
Spatial heterogeneity and oxygen dependence of glucose consumption in R3230Ac and fibrosarcomas of the Fischer 344 rat. Cancer Res (2005) 1.81
Stable isotope resolved metabolomics of lung cancer in a SCID mouse model. Metabolomics (2011) 1.73
Mice lacking brain/kidney phosphate-activated glutaminase have impaired glutamatergic synaptic transmission, altered breathing, disorganized goal-directed behavior and die shortly after birth. J Neurosci (2006) 1.55
The oncoprotein H-RasV12 increases mitochondrial metabolism. Mol Cancer (2007) 1.33
Stable isotope-resolved metabolomic analysis of lithium effects on glial-neuronal metabolism and interactions. Metabolomics (2010) 1.23
Hypoxia divergently regulates production of reactive oxygen species in human pulmonary and coronary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol (2007) 1.16
c-Myc-regulated microRNAs modulate E2F1 expression. Nature (2005) 31.81
Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res (2003) 14.79
Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics (2010) 13.35
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature (2009) 13.28
HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab (2006) 13.22
Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet (2007) 10.78
Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer (2011) 9.68
Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol (2009) 9.67
Cancer's molecular sweet tooth and the Warburg effect. Cancer Res (2006) 7.24
Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). Metabolomics (2007) 6.93
HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell (2007) 6.31
HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell (2007) 6.06
Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell (2011) 5.63
Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci U S A (2006) 5.27
Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell (2010) 5.02
Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol Cell Biol (2005) 4.99
Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A (2010) 4.97
HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell (2007) 4.81
Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci U S A (2008) 4.79
An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol (2003) 4.49
Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood (2009) 4.22
Candidate exome capture identifies mutation of SDCCAG8 as the cause of a retinal-renal ciliopathy. Nat Genet (2010) 3.99
The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab (2012) 3.81
Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc Natl Acad Sci U S A (2009) 3.76
IDPicker 2.0: Improved protein assembly with high discrimination peptide identification filtering. J Proteome Res (2009) 3.72
Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol (2007) 3.51
Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol (2006) 3.35
Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell (2013) 3.32
Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res (2010) 3.30
Repeatability and reproducibility in proteomic identifications by liquid chromatography-tandem mass spectrometry. J Proteome Res (2010) 3.08
Altered regulation of metabolic pathways in human lung cancer discerned by (13)C stable isotope-resolved metabolomics (SIRM). Mol Cancer (2009) 3.05
Multifaceted roles of glycolytic enzymes. Trends Biochem Sci (2005) 3.01
Cadmium is a mutagen that acts by inhibiting mismatch repair. Nat Genet (2003) 2.88
Rice plants take up iron as an Fe3+-phytosiderophore and as Fe2+. Plant J (2006) 2.82
Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science (2009) 2.76
Identification of S-nitrosylation motifs by site-specific mapping of the S-nitrosocysteine proteome in human vascular smooth muscle cells. Proc Natl Acad Sci U S A (2006) 2.58
Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem J (2007) 2.52
Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res (2004) 2.50
Sample preparation and digestion for proteomic analyses using spin filters. Proteomics (2005) 2.49
Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res (2004) 2.44
Interlaboratory study characterizing a yeast performance standard for benchmarking LC-MS platform performance. Mol Cell Proteomics (2009) 2.39
Specific patterns of electrophile adduction trigger Keap1 ubiquitination and Nrf2 activation. J Biol Chem (2005) 2.37
Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol Cell Proteomics (2014) 2.37
Identification of sensor cysteines in human Keap1 modified by the cancer chemopreventive agent sulforaphane. Chem Res Toxicol (2005) 2.22
Evaluation of myc E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays. Mol Cell Biol (2004) 2.19
Global regulation of nucleotide biosynthetic genes by c-Myc. PLoS One (2008) 2.12
Performance metrics for liquid chromatography-tandem mass spectrometry systems in proteomics analyses. Mol Cell Proteomics (2009) 2.09
Pharmacological mechanisms of 5-HT₃ and tachykinin NK₁ receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol (2012) 2.07
Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity. Immunity (2013) 2.05
Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proc Natl Acad Sci U S A (2012) 2.02
Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis. Mol Cell Biol (2006) 2.01
Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med (2012) 2.00
High-affinity near-infrared fluorescent small-molecule contrast agents for in vivo imaging of prostate-specific membrane antigen. Mol Imaging (2005) 1.97
Global analysis of protein damage by the lipid electrophile 4-hydroxy-2-nonenal. Mol Cell Proteomics (2008) 1.89
Isotopomer-based metabolomic analysis by NMR and mass spectrometry. Methods Cell Biol (2008) 1.84
Identification of protein targets of 4-hydroxynonenal using click chemistry for ex vivo biotinylation of azido and alkynyl derivatives. Chem Res Toxicol (2008) 1.82
Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol (2009) 1.81
Targeting aspartate aminotransferase in breast cancer. Breast Cancer Res (2008) 1.78
Pyruvate carboxylase is critical for non-small-cell lung cancer proliferation. J Clin Invest (2015) 1.74
Stable isotope resolved metabolomics of lung cancer in a SCID mouse model. Metabolomics (2011) 1.73
Cytosolic and nuclear protein targets of thiol-reactive electrophiles. Chem Res Toxicol (2006) 1.69
Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. J Clin Invest (2015) 1.67
Equivalence of protein inventories obtained from formalin-fixed paraffin-embedded and frozen tissue in multidimensional liquid chromatography-tandem mass spectrometry shotgun proteomic analysis. Mol Cell Proteomics (2009) 1.66
Rice metal-nicotianamine transporter, OsYSL2, is required for the long-distance transport of iron and manganese. Plant J (2010) 1.66
c-myc overexpression causes anaplasia in medulloblastoma. Cancer Res (2006) 1.66
MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS One (2010) 1.65
P-Mod: an algorithm and software to map modifications to peptide sequences using tandem MS data. J Proteome Res (2005) 1.65
Therapeutic targeting of cancer cell metabolism. J Mol Med (Berl) (2011) 1.62
Protein identification using customized protein sequence databases derived from RNA-Seq data. J Proteome Res (2011) 1.62
Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol (2004) 1.62
Staphylococcus aureus fur regulates the expression of virulence factors that contribute to the pathogenesis of pneumonia. Infect Immun (2010) 1.59
Expression profile of tyrosine kinases in breast cancer. Clin Cancer Res (2002) 1.58
Interleukin-27R (WSX-1/T-cell cytokine receptor) gene-deficient mice display enhanced resistance to leishmania donovani infection but develop severe liver immunopathology. Am J Pathol (2006) 1.57
Global shifts in protein sumoylation in response to electrophile and oxidative stress. Chem Res Toxicol (2004) 1.57
A strategy for identifying transcription factor binding sites reveals two classes of genomic c-Myc target sites. Proc Natl Acad Sci U S A (2003) 1.56
Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS. Mol Cell Proteomics (2012) 1.55
Evaluation of strong cation exchange versus isoelectric focusing of peptides for multidimensional liquid chromatography-tandem mass spectrometry. J Proteome Res (2008) 1.55
Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J (2006) 1.55
Methods for peptide and protein quantitation by liquid chromatography-multiple reaction monitoring mass spectrometry. Mol Cell Proteomics (2011) 1.54